Company Of The Day: Boston Scientific
What?
Boston Scientific (NYSE:BSX) closed its acquisition of Baylis Medical, a company that offers advanced transseptal access solutions and products used to support heart procedures.
Why?
- Should You Pick Boston Scientific Stock After A Solid Q4 And 13% Uptick This Year?
- What’s Next For Boston Scientific Stock After 5% Gains In A Week?
- Should You Pick MGM Resorts Over Boston Scientific Stock For Better Returns?
- Which Is A Better Buy – Boston Scientific Stock Or Abbott?
- What’s Next For Boston Scientific Stock After Outperforming During The 2022 Inflation Shock?
- New Product Launches To Aid Boston Scientific’s Q1
With the $1.75 billion deal, Boston Scientific will be able to strengthen its position in multiple high-growth cardiology markets.
So What?
We think BSX stock is undervalued at current levels. We value BSX at about $50 per share, about 15% ahead of the current market price.
See Our Complete Analysis For Boston Scientific
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since the end of 2016.
| Returns | Feb 2022 MTD [1] |
2022 YTD [1] |
2017-22 Total [2] |
| BSX Return | 3% | 4% | 104% |
| S&P 500 Return | -1% | -6% | 100% |
| Trefis MS Portfolio Return | 2% | -8% | 264% |
[1] Month-to-date and year-to-date as of 2/17/2022
[2] Cumulative total returns since the end of 2016